Xponance Inc. Has $1.13 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Xponance Inc. lessened its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 7.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,728 shares of the biotechnology company’s stock after selling 882 shares during the period. Xponance Inc.’s holdings in Sarepta Therapeutics were worth $1,131,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Vontobel Holding Ltd. increased its stake in shares of Sarepta Therapeutics by 12.8% in the fourth quarter. Vontobel Holding Ltd. now owns 25,278 shares of the biotechnology company’s stock valued at $2,438,000 after buying an additional 2,863 shares during the period. WCM Investment Management LLC acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $600,000. Sapient Capital LLC acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $978,000. Tobam increased its stake in shares of Sarepta Therapeutics by 4.8% in the fourth quarter. Tobam now owns 156,046 shares of the biotechnology company’s stock valued at $15,048,000 after buying an additional 7,105 shares during the period. Finally, International Assets Investment Management LLC increased its stake in shares of Sarepta Therapeutics by 9,382.5% in the fourth quarter. International Assets Investment Management LLC now owns 11,379 shares of the biotechnology company’s stock valued at $1,097,000 after buying an additional 11,259 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $124.25 on Thursday. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $11.67 billion, a price-to-earnings ratio of -20.30 and a beta of 0.94. The stock has a 50 day moving average of $126.18 and a 200 day moving average of $110.31. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. The company had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. Sarepta Therapeutics’s revenue was up 53.6% on a year-over-year basis. During the same period last year, the business posted ($1.24) earnings per share. As a group, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares of the company’s stock, valued at $3,457,550.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares of the company’s stock, valued at $3,457,550.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kathryn Jean Boor sold 761 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares of the company’s stock, valued at $923,941.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SRPT. Royal Bank of Canada increased their price target on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. Wedbush reissued an “outperform” rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Barclays upped their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Citigroup upped their target price on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $128.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $158.38.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.